It is speculated that Ad-VT is a promising drug for the treatment of gemcitabine- or paclitaxel-resistant NSCLC, with previous studies reporting that persistent elevated P-gp expression increases the resistance of DOX-resistant CH27 cells to DOX [27]. Here, PGP is linked to non-small cell lung carcinoma.